InnoCore Pharmaceuticals, a privately owned pharma located in the Netherlands, has signed an exclusive license and collaboration agreement with Allergan, a multi-specialty healthcare company headquartered in Irvine, Calif.

The companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases. Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan’s proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection. The SynBiosys drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods of time, ranging from weeks to many months.